Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchestra BioMed HoldingsOBIO +7.00%42 Gross Margin % is 71.59% as of Jun. 2026, which is 25% below its 10-year median of 95.75. GuruFocus rates OBIO with a GF Score™ of 42/100 and a GF Value™ of $31.58 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 737 Biotechnology companies, Orchestra BioMed Holdings ranks better than 97.83% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orchestra BioMed Holdings had a gross margin of 71.59% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Orchestra BioMed Holdings Gross Margin % Related Terms
Orchestra BioMed Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBIO vs CYDY, IRD, VNDA: Gross Margin % Comparison
For the Biotechnology subindustry, Orchestra BioMed Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orchestra BioMed Holdings (OBIO) has a Gross Margin % of 71.59% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Orchestra BioMed Holdings and its competitors. This is 25% below median its historical median of 95.75. Over the past decade, Orchestra BioMed Holdings' Gross Margin % has ranged from 92.27 to 125.45. According to the industry distribution chart, Orchestra BioMed Holdings ranks #16 out of 737 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Orchestra BioMed Holdings' Gross Margin % too high?
Orchestra BioMed Holdings' current Gross Margin % of 71.59% is 25% below median its 10-year median of 95.75. Over the past 10 years, this metric has ranged from a low of 92.27 to a high of 125.45. The Biotechnology industry median Gross Margin % is 60.91. Orchestra BioMed Holdings' value of 71.59% is 17.5% above this industry median. Based on the distribution chart, Orchestra BioMed Holdings ranks #16 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Gross Margin % compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #16 out of 737 companies for Gross Margin %. This places Orchestra BioMed Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Orchestra BioMed Holdings' value of 71.59% is 17.5% above this benchmark. Historically, Orchestra BioMed Holdings' own Gross Margin % has ranged from 92.27 to 125.45 over the past decade. While the company's 10-year median is 95.75 vs. the industry median of 60.91, Orchestra BioMed Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchestra BioMed Holdings's current Gross Margin % of 71.59% is 17.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Orchestra BioMed Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchestra BioMed Holdings's current Gross Margin % is 71.59%, which is 25% below median its own 10-year median of 95.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.58, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Gross Margin % is 71.59%, which is 25% below median its 10-year median of 95.75 and 17.5% above the Biotechnology industry median of 60.91. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Gross Margin % is 71.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Gross Margin %: 71.59% (25% below median its 10-year median of 95.75)
GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
Industry Position: 17.5% above the Biotechnology median (#16 of 737)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
